首頁 > 市場調查報告書 > 製藥

個人化醫學

市場調查報告書

商品編碼

1533623

伴同性診斷市場規模、佔有率和成長分析：按產品/服務、技術、適應症和地區 - 產業預測，2024-2031 年

Companion Diagnostics Market Size, Share, Growth Analysis, By Product and Services (Assays, Kits, Reagents, Software & Services), By Technology (PCR, ISH), By Indication (Cardiovascular, Oncology), By Region - Industry Forecast 2024-2031

出版日期: 2024年08月02日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球伴同性診斷市場規模將為66.2億美元，從2023年的73.7億美元成長到2031年的174.8億美元，並且預計在預測期內（2024-2031年）將以複合年成長率成長。年為11.4%。

伴同性診斷對於安全有效地使用某些生物製藥和藥物至關重要，特別是在癌症的診斷和治療中。這些測試對於透過識別特定的生物標記為個別患者量身定做治療策略至關重要。例如，Foundation Medicine 的 FOUNDATIONONE CDx 是一種出色的伴同性診斷，可對 300 多個癌症相關基因進行全面分析。這種詳細的基因分析提供了重要的見解，將有助於指導針對各種固體癌的標靶治療和個人化癌症治療的選擇。伴同性診斷使醫療保健專業人員能夠做出明智的治療方法，從而顯著提高根據患者個體需求量身定做的癌症治療的有效性和安全性。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

IDEXX Laboratories, Inc.（US）
Zoetis Inc.（US）
Heska Corporation（US）
Thermo Fisher Scientific, Inc.（US）
Virbac SA（France）
IDVet（France）
NEOGEN Corporation（US）
bioMerieux SA（France）
Randox Laboratories Ltd.（UK）
AniCell Biotech（US）
Bionote Inc.（South Korea）
Bio-Rad Laboratories, Inc.（US）
Antech Diagnostics（US）
Eurofins Scientific SE（Luxembourg）
Animalytix LLC（US）
Advanced Animal Diagnostics（US）
Roche Diagnostics（Switzerland）
Agilent Technologies, Inc.（US）
Myriad Genetics, Inc.（US）
Illumina, Inc.（US）
Qiagen NV（Netherlands）

簡介目錄

Product Code: SQMIG35A2649

Global Companion Diagnostic Market size was valued at USD 6.62 billion in 2022 and is poised to grow from USD 7.37 billion in 2023 to USD 17.48 billion by 2031, growing at a CAGR of 11.4% in the forecast period (2024-2031).

Companion diagnostics are essential for the safe and effective use of specific biological products or medications, especially in cancer diagnosis and treatment. These tests are pivotal in customizing therapeutic strategies for individual patients by identifying particular biomarkers. For instance, Foundation Medicine's FOUNDATIONONE CDx is a notable companion diagnostic that offers a thorough analysis of over 300 cancer-related genes. This detailed genetic analysis provides critical insights that help in selecting targeted and personalized cancer treatments for a wide range of solid tumors. By enabling healthcare professionals to make well-informed decisions about treatment options, companion diagnostics significantly improve both the efficacy and safety of cancer therapies tailored to individual patient needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Companion Diagnostic market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Companion Diagnostic Market Segmental Analysis

The Companion Diagnostic Market is segmented based on product and services, Technology, indication and region. Based on product and services, the market is segmented into assay kits and reagents, and software and services. Based on industry, the market is segmented into polymerase chain reaction, immunohistochemistry, in situ hybridization, and next-generation sequencing, among others. Based on indication, the market is segmented into oncology, neurology, and others. Based on region, the market is segmented into North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

Drivers of the Global Companion Diagnostic Market

Recent years have seen a significant rise in cancer cases, leading to increased demand for effective Companion Diagnostic (CDx) assays. This growing prevalence highlights the importance of genomic testing, which provides a detailed understanding of tumors' genetic profiles. Genomic testing helps characterize the genetic makeup of tumors and offers precise guidance to healthcare professionals on appropriate treatment strategies. Consequently, the rise in cancer cases is driving up sales of CDx products. These diagnostics are crucial for personalizing treatment approaches, ensuring that patients receive targeted therapies based on their tumors' specific genetic features, and ultimately improving the effectiveness of cancer care.

Restraints in the Global Companion Diagnostic Market

Despite the increasing acceptance of companion diagnostic tests, a significant challenge remains due to the lack of a standardized method for setting reimbursement rates. Currently, these rates are determined on a case-by-case basis, leading to inconsistencies in the reimbursement process. For instance, our analysis reveals that in Germany, there is a notable variance in reimbursement structures between inpatient and outpatient care settings. In the inpatient system, diagnostics are generally covered under diagnosis-related groups, which provides a standardized approach within this context.

Market Trends of the Global Companion Diagnostic Market

Clinicians use Next-Generation Sequencing (NGS) to analyze a broad array of genes related to cancer development, utilizing surgically excised tumor samples from patients. NGS is distinguished by its ability to produce extensive genetic data quickly, making it a crucial tool in oncology. Ongoing technological advancements continue to improve the accuracy and effectiveness of this sequencing technique. According to a publication by the Centers for Disease Control and Prevention (CDC), NGS has evolved from being primarily a research tool to becoming a central element in clinical applications over the past five years. This transition highlights NGS's growing importance in understanding the genetic complexities of cancers, which enhances the precision and effectiveness of diagnostic and treatment strategies in clinical practice.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Supply Chain Analysis
Trade Analysis
Ecosystem of the Market
Start-up Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Market Attractive Index
Degree of Competition

Companion Diagnostic Market by Product & Service

Market Overview
Assays, Kits, and Reagents
Instruments & Systems
Software & Services

Companion Diagnostic Market by Technology

Market Overview
Polymerase Chain Reaction
In Situ Hybridization
Next-Generation Sequencing
Immunohistochemistry
Other Technologies

Companion Diagnostic Market by Indication

Market Overview
Cancer
- Lung Cancer
- Breast Cancer
- Blood Cancer
- Colorectal Cancer
- Other Cancer
Neurological Diseases
Cardiovascular Diseases
Infectious Diseases
Other Indications

Companion Diagnostic Market by sample Types

Market Overview
Tissue Samples
Blood Samples
Other Sample types

Companion Diagnostic Market by End-User

Market Overview
Pharmaceutical & Biotechnology Companies
Reference Laboratories
Healthcare and Pharmaceutical
Other End Users

Companion Diagnostic Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

IDEXX Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zoetis Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Heska Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Virbac SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IDVet (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NEOGEN Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Randox Laboratories Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AniCell Biotech (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bionote Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Antech Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific SE (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Animalytix LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Advanced Animal Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Diagnostics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments